CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2528793&ei=knKaUvD6OuTX0QGcJA&usg=AFQjCNFQ7k5AQVVXqwKgQkla2kL3LOpxkg
Epizyme Forms Strategic Partnership With Celgene Corporation's Celgene International Sàrl
Thursday, 26 Apr 2012 07:15am EDT
Epizyme and Celgene International Sàrl, a subsidiary of Celgene Corporation announced the formation of a strategic partnership to discover, develop and commercialize personalized therapeutics for patients with genetically-defined cancers by inhibiting histone methyltransferases (HMTs), an important epigenetic target class. Under the terms of the agreement, Celgene receives the exclusive option to license ex-US rights to Epizyme’s available HMT inhibitor programs during an initial three-year period and has the right to extend this option period for one year with additional funding. Epizyme and Celgene will work jointly to discover and develop HMT inhibitors and will co-fund global development of the collaboration programs. Epizyme retains all US rights to the collaboration programs and receives a $90 million upfront payment, which includes an equity investment. 
